{"id":72,"date":"2022-08-19T19:15:24","date_gmt":"2022-08-19T19:15:24","guid":{"rendered":"https:\/\/kurir-health.com\/?p=72"},"modified":"2023-05-25T11:47:02","modified_gmt":"2023-05-25T11:47:02","slug":"successful-completion-of-toxicity-study-for-can10-antibody-by-cantargia-paves-the-way-for-phase-i-clinical-trial-application","status":"publish","type":"post","link":"https:\/\/kurir-health.com\/?p=72","title":{"rendered":"Successful completion of toxicity study for CAN10 antibody by Cantargia paves the way for phase I clinical trial application"},"content":{"rendered":"\n<p>Cantargia AB (Nasdaq Stockholm CANTA) has announced the conclusion of its Good Laboratory Practices (GLP) toxicity studies for CAN10, an anti-inflammatory IL1RAP binding antibody.&nbsp;The study showed that CAN10 is well tolerated if administered for six weeks.&nbsp;Cantargia intends to begin the phase I clinical trials for CAN10 in the first half 2023.<\/p>\n\n\n\n<p>In the current GLP toxicity test, CAN10 intravenously was administered once weekly over six weeks, at doses of up to 50mg\/kg. This is far above the clinically recommended dose levels.&nbsp;CAN10 at 5mg\/kg was administered subcutaneously.&nbsp;CAN10 was administered intravenously or subcutaneously without any adverse effects.&nbsp;The administration of CAN10 did not cause any changes in body weight or respiratory, cardiovascular or neurological functions.&nbsp;No changes were observed in the clinical pathology, e.g.&nbsp;Hematology, serum chemistry (coagulation and urinalysis), or microscopic evaluations of selected tissues.&nbsp;The regulatory authorities require that the GLP toxicology study be completed before clinical trials can begin.<\/p>\n\n\n\n<p>Cantargia will submit a phase I clinical trial application to regulatory authorities as a next step to the development of CAN10 once administrative procedures are finalized.&nbsp;Cantargia will start the study based on the timeline for regulatory review. However, the treatment of healthy participants could begin as soon as the first half 2023.<\/p>\n\n\n\n<p>CAN10, Cantargia\u2019s second program of development, extends Cantargia\u2019s IL1RAP technology beyond oncology and into inflammatory and autoimmune disorders. The initial focus is on systemic sclerosis (SS) and myocarditis.&nbsp;Cantargia published preclinical data in 2022 demonstrating a CAN10-surrogate antibody&#8217;s strong treatment effects in different in vivo diseases models.&nbsp;The CAN10 antibody, for example, was shown to reduce skin fibrosis in models of systemic sclerosis and affected relevant proinflammatory markers.&nbsp;The CAN10 surrogate antibody also reduced inflammation in myocarditis models caused by viral or autoimmune disease.&nbsp;These effects are a result of CAN10&#8217;s broad and specific mechanisms that modify the activity of IL1RAP, the target molecule.<\/p>\n\n\n\n<p>We are very excited by the progress of the CAN10 Program, which has shown a positive safety profile and powerful treatment effects on several models of life-threatening inflammatory disease.&nbsp;Goran Forsberg is CEO of Cantargia. He said that we are ready to submit an application for approval to begin the first clinical trials for this unique, promising and leading candidate ,&#8221;.<\/p>\n\n\n\n<p>Cantargia&#8217;s stock is traded on Nasdaq Stockholm under the ticker CANTA.\u00a0You can find out more about Cantargia at www.cantargia.com.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/kurir-health.com\/wp-content\/uploads\/2023\/05\/image-43.png\" alt=\"\" class=\"wp-image-215\" srcset=\"https:\/\/kurir-health.com\/wp-content\/uploads\/2023\/05\/image-43.png 768w, https:\/\/kurir-health.com\/wp-content\/uploads\/2023\/05\/image-43-300x169.png 300w\" sizes=\"auto, (max-width: 768px) 100vw, 768px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Cantargia AB (Nasdaq Stockholm CANTA) has announced the conclusion of its Good Laboratory Practices (GLP) toxicity studies for CAN10, an anti-inflammatory IL1RAP binding antibody.&nbsp;The study showed that CAN10 is well tolerated if administered for six weeks.&nbsp;Cantargia intends to begin the phase I clinical trials for CAN10 in the first half 2023. In the current GLP [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":215,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-72","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-trials"],"_links":{"self":[{"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/posts\/72","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kurir-health.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72"}],"version-history":[{"count":2,"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/posts\/72\/revisions"}],"predecessor-version":[{"id":297,"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/posts\/72\/revisions\/297"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/media\/215"}],"wp:attachment":[{"href":"https:\/\/kurir-health.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kurir-health.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kurir-health.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}